CN116474108A - 成纤维细胞活化蛋白(fap)-靶向成像和治疗 - Google Patents

成纤维细胞活化蛋白(fap)-靶向成像和治疗 Download PDF

Info

Publication number
CN116474108A
CN116474108A CN202310269637.XA CN202310269637A CN116474108A CN 116474108 A CN116474108 A CN 116474108A CN 202310269637 A CN202310269637 A CN 202310269637A CN 116474108 A CN116474108 A CN 116474108A
Authority
CN
China
Prior art keywords
conjugate
jfl
fap
pharmaceutically acceptable
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310269637.XA
Other languages
English (en)
Chinese (zh)
Inventor
P.S.罗
J.罗伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of CN116474108A publication Critical patent/CN116474108A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202310269637.XA 2016-12-14 2017-12-13 成纤维细胞活化蛋白(fap)-靶向成像和治疗 Pending CN116474108A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662434380P 2016-12-14 2016-12-14
US62/434380 2016-12-14
US201762575050P 2017-10-20 2017-10-20
US62/575050 2017-10-20
PCT/US2017/065995 WO2018111989A1 (en) 2016-12-14 2017-12-13 Fibroblast activation protein (fap)-targeted imaging and therapy
CN201780086490.3A CN110291401B (zh) 2016-12-14 2017-12-13 成纤维细胞活化蛋白(fap)-靶向成像和治疗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780086490.3A Division CN110291401B (zh) 2016-12-14 2017-12-13 成纤维细胞活化蛋白(fap)-靶向成像和治疗

Publications (1)

Publication Number Publication Date
CN116474108A true CN116474108A (zh) 2023-07-25

Family

ID=62559225

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310269637.XA Pending CN116474108A (zh) 2016-12-14 2017-12-13 成纤维细胞活化蛋白(fap)-靶向成像和治疗
CN201780086490.3A Active CN110291401B (zh) 2016-12-14 2017-12-13 成纤维细胞活化蛋白(fap)-靶向成像和治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780086490.3A Active CN110291401B (zh) 2016-12-14 2017-12-13 成纤维细胞活化蛋白(fap)-靶向成像和治疗

Country Status (6)

Country Link
US (4) US20200237936A1 (https=)
EP (1) EP3555627B1 (https=)
JP (1) JP7162592B2 (https=)
CN (2) CN116474108A (https=)
ES (1) ES2972577T3 (https=)
WO (1) WO2018111989A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
EA202090776A1 (ru) 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
JP2021506972A (ja) 2017-12-15 2021-02-22 プラクシス バイオテック エルエルシー 線維芽細胞活性化タンパク質の阻害剤
SG11202007180QA (en) * 2018-02-06 2020-08-28 Univ Heidelberg Fap inhibitor
WO2019154859A1 (en) * 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor
KR20210042125A (ko) * 2018-08-07 2021-04-16 퍼듀 리서치 파운데이션 Car t 세포의 회생
US11426472B2 (en) 2018-10-17 2022-08-30 Purdue Research Foundation Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis
CN113811529A (zh) * 2018-12-21 2021-12-17 普拉西斯生物技术有限责任公司 成纤维细胞激活蛋白抑制剂
CN118406106A (zh) 2019-07-08 2024-07-30 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
WO2021016392A1 (en) * 2019-07-22 2021-01-28 Purdue Research Foundation Multivalent fibroblast-targeted agents and methods of use
WO2021055641A1 (en) * 2019-09-17 2021-03-25 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases
WO2021155292A1 (en) * 2020-01-31 2021-08-05 Philip Stewart Low Fibroblast activation protein (fap) - targeted antifibrotic therapy
EP3891138B1 (en) 2020-02-12 2022-01-12 Philochem AG Fibroblast activation protein ligands for targeted delivery applications
CN115697413B (zh) * 2020-03-24 2025-08-01 塔夫茨大学信托人 靶向fap的放射性药物和显像剂以及与之相关的用途
EP4132921A4 (en) * 2020-04-09 2024-03-27 Purdue Research Foundation Pi3 kinase inhibitors and uses thereof
CA3176497A1 (en) 2020-05-07 2021-11-11 Fatima MECHTA-GRIGORIOU Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
TW202241516A (zh) * 2020-12-17 2022-11-01 美商杜夫特學院信託管理公司 經fap活化之放射性治療診斷(radiotheranostics)，與其相關用途
CN114790195B (zh) * 2020-12-21 2024-05-17 苏州药明博锐生物科技有限公司 成纤维细胞活化蛋白抑制剂
EP4043452A1 (en) 2021-02-12 2022-08-17 Philochem AG Bivalent fibroblast activation protein ligands for targeted delivery applications
JP2024506644A (ja) * 2021-02-12 2024-02-14 フィロケム・アーゲー 標的送達に適用するための二価線維芽細胞活性化タンパク質リガンド
US20240238458A1 (en) * 2021-03-16 2024-07-18 Purdue Research Foundation Compounds targeting fibroblast-activation protein and methods of use thereof
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
EP4313033A4 (en) * 2021-03-24 2025-04-23 Trustees Of Tufts College BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS
AU2022275579C1 (en) * 2021-05-19 2024-08-22 Ferronova Pty Ltd Mapping nanoparticles
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
CN113521313A (zh) * 2021-07-22 2021-10-22 戴格普瑞生物科技(苏州)有限公司 靶向造影剂、产品、制备方法及应用
WO2023040828A1 (zh) * 2021-09-14 2023-03-23 菲柏生物医学技术（广州）有限公司 靶向FAP阳性细胞的siRNA缀合物及其药物组合物和应用
MX2024004077A (es) 2021-10-04 2024-04-18 Philochem Ag Ligandos de proteina de activacion de fibroblastos radioetiquetados.
CN118574618A (zh) * 2021-11-03 2024-08-30 艾德森特克斯治疗股份有限公司 药物偶联物及其制备与使用方法
US20250177582A1 (en) 2022-01-30 2025-06-05 Philochem Ag High-affinity ligands of fibroblast activation protein for targeted delivery applications
CN114214061B (zh) * 2022-02-22 2022-05-17 北京大学 一种聚乙二醇修饰的两性离子化荧光探针、制剂及其应用
CN119816493A (zh) 2022-09-06 2025-04-11 菲罗化学股份公司 用于靶向递送应用的多价成纤维细胞激活蛋白配体
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
AU2023347470A1 (en) 2022-09-23 2025-04-10 Nuclidium Ag High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
WO2024102956A1 (en) * 2022-11-09 2024-05-16 Purdue Research Foundation Keto-amide-based fibroblast activation protein-targeted ligand linked to an imaging or therapeutic agent, compositions and methods of use
KR20260006628A (ko) * 2023-05-08 2026-01-13 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 섬유아세포 활성화 단백질을 표적화하는 리간드
CN116621823B (zh) * 2023-07-06 2023-10-31 南京诺源医疗器械有限公司 诊断转移淋巴结近红外荧光示踪剂、合成方法及应用
CN121752300A (zh) 2023-08-31 2026-03-27 荷兰拉德堡德大学学术医学中心 子宫内膜异位症示踪剂

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767242A (en) 1994-04-20 1998-06-16 Boehringer Ingelheim Int'l Gmbh Isolated dimeric fibroblast activation protein alpha, and uses thereof
US5851775A (en) 1997-03-20 1998-12-22 Johns Hopkins University β-catenin, Tcf-4, and APC interact to prevent cancer
US20020004490A1 (en) 1999-04-12 2002-01-10 Dean Nicholas M. Antisense modulation of Fas mediated signaling
WO1999047152A2 (en) 1998-03-20 1999-09-23 Sloan Kettering Institute For Cancer Research Use of dipeptidyl peptidase (dpp4) of fibroblast activating protein alpha for suppressing the malignant phenotype of cancer cells
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
GB9827430D0 (en) 1998-12-11 1999-02-03 Ludwig Inst Cancer Res Differential expression in primary breast cancer
CA2391534A1 (en) * 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
JP2003530092A (ja) 2000-03-17 2003-10-14 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ヒトＦＡＰ−α−特異抗体
US20090010919A1 (en) 2004-07-29 2009-01-08 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated With Fibroblast Activation Protein (Fap)
US7374898B2 (en) 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
US20090238862A1 (en) 2004-10-27 2009-09-24 Wen-Tien Chen Methods and Compositions for Seprase Inactivation
EP1943257A2 (en) 2005-05-19 2008-07-16 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
KR20080030079A (ko) 2005-07-05 2008-04-03 트러스티즈 오브 터프츠 칼리지 섬유아세포 활성 단백질 알파의 억제제
EP1760076A1 (en) 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
EP1963537A4 (en) 2005-12-14 2009-11-11 Ludwig Inst For Cancer Res Ltd METHOD FOR DIAGNOSING RHEUMATOID ARTHRITIS BY TESTING MYOFIBROBLASTIC-SIMILAR SYNOVOCYTES FOR A FIBROBLAST ACTIVATION PROTEIN
WO2007087131A2 (en) 2006-01-05 2007-08-02 The Johns Hopkins University Peptide prodrugs
CA2658331A1 (en) 2006-06-07 2007-12-21 Patrick A. Mckee Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use
PL2035581T3 (pl) 2006-06-21 2013-01-31 Scripps Research Inst Kompozycja DNA przeciwko FAP - antygenowi zrębowemu nowotworu i sposoby jej stosowania
EP1882741B1 (en) 2006-07-25 2010-06-30 Institut Pasteur Recombinant Mycobacterium strain expressing a mycobacterial FAP protein under the control of a promoter active under hypoxia and its application for cancer therapy
BRPI0716368A2 (pt) 2006-08-29 2013-10-01 Molecular Insight Pharm Inc porÇÕes de radioimageamento acopladas a porÇÕes de ligaÇço Á peptidase para imageamento de tecidos e àrgços que expressam peptidases
WO2008116053A2 (en) 2007-03-20 2008-09-25 Trustees Of Tufts College Fap-activated chemotherapeutic compounds, and methods of use thereof
WO2008116054A1 (en) 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
EP4464384A3 (en) 2007-08-17 2025-01-08 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
BRPI0815405A2 (pt) 2007-08-17 2015-02-03 Boehringer Ingelheim Int Compostos derivados de purina, processo para a preparação de uma composição farmacêutica e uso dos mesmos
MX2010004671A (es) 2007-12-10 2010-05-27 Hoffmann La Roche Seprasa como marcador para cancer.
EP2285989B1 (en) 2008-05-15 2016-11-16 The University of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
DK2291640T3 (en) * 2008-05-20 2019-03-11 Univ Health Network Device and method for fluorescence-based imaging and monitoring
WO2010036814A1 (en) 2008-09-25 2010-04-01 Molecular Insight Pharmaceuticals, Inc. Selective seprase inhibitors
WO2010083570A1 (en) 2009-01-23 2010-07-29 The University Of Sydney Novel metabolic disease therapy
US10815517B2 (en) 2009-04-28 2020-10-27 Roche Diagnostics Operations, Inc. Use of DPPIV/seprase as a marker for cancer
EP2483316A1 (en) 2009-10-02 2012-08-08 Ludwig Institute for Cancer Research Ltd. Anti-fibroblast activation protein antibodies and methods and uses thereof
WO2011040973A2 (en) * 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
EP2397466B1 (en) 2010-06-15 2012-11-28 Centre National De La Recherche Scientifique CNRS X-ray and gamma-photon activatable organic compounds, their preparation and their uses
AU2011295030B2 (en) 2010-08-27 2016-01-28 University Of Zurich A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
CN108383893A (zh) 2011-08-30 2018-08-10 塔夫茨大学信托人 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂
WO2013107820A1 (en) * 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
US9688722B2 (en) 2012-05-04 2017-06-27 The Board Of Regents Of The University Of Oklahoma Substrates and inhibitors of prolyl oligopeptidase and methods of use
US20150320892A1 (en) 2012-06-29 2015-11-12 Ge Healthcare Limited Imaging fibrosis
WO2014022636A1 (en) 2012-08-02 2014-02-06 Trustees Of Tufts College Broad spectrum inhibitors of the post proline cleaving enzymes for treatment of hepatitis c virus infections
WO2014055442A2 (en) * 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
WO2014072465A1 (en) 2012-11-09 2014-05-15 Roche Diagnostics Gmbh In vitro capture and analysis of circulating tumor cells
US9402888B2 (en) 2013-03-14 2016-08-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
WO2014149069A1 (en) * 2013-03-15 2014-09-25 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2014167083A1 (en) 2013-04-12 2014-10-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia
EP3001813B1 (en) 2013-05-13 2019-03-27 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
CN103267852B (zh) 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
EP3102242A2 (en) * 2014-02-03 2016-12-14 Philochem AG Targeted drug conjugates
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
JP6744826B2 (ja) * 2014-06-13 2020-08-19 バック バイオサイエンシーズ, エルエルシーBach BioSciences, LLC Ｆａｐ活性化治療剤及びそれに関連する使用
EP3204412B1 (en) 2014-10-08 2020-08-19 F.Hoffmann-La Roche Ag Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
WO2016089879A1 (en) * 2014-12-01 2016-06-09 Endocyte, Inc. Conjugates of garftase inhibitors
CA2973040A1 (en) 2015-01-09 2016-07-14 Mabimmune Diagnostics Ag Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof
WO2016146174A1 (en) 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
WO2016164815A1 (en) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US20160303251A1 (en) * 2015-04-17 2016-10-20 Endocyte, Inc. Conjugates of garftase inhibitors
HRP20240215T1 (hr) 2016-03-22 2024-04-26 The Johns Hopkins University Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate
WO2017189569A1 (en) 2016-04-25 2017-11-02 Trustees Of Tufts College Multimediator dpp4 and fap inhibitors, and uses related thereto
CN105949282B (zh) 2016-06-20 2020-06-16 郑州大学 一种靶向fap的抗血管生成肽z-gp-v2及其应用
CN106046121B (zh) 2016-06-20 2020-06-16 郑州大学 一种靶向fap的抗血管生成肽z-gp-v1及其应用
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
EP3606939A4 (en) 2017-04-04 2021-01-20 F. Hoffmann-La Roche AG SUBSTRATES RECOGNIZED BY FIBROBLAST ACTIVATION PROTEIN (FAP) AND METHOD OF USING THEM
EA202090776A1 (ru) * 2017-10-23 2020-07-27 Дзе Джонс Хопкинс Юниверсити Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)
CN109796532B (zh) 2017-11-17 2024-09-10 恺兴生命科技(上海)有限公司 靶向成纤维激活蛋白α的结合单元及其应用
CN108152258A (zh) 2017-12-13 2018-06-12 清华大学 一种检测待测溶液中氨基糖苷类抗生素的含量的方法
JP2021506972A (ja) 2017-12-15 2021-02-22 プラクシス バイオテック エルエルシー 線維芽細胞活性化タンパク質の阻害剤
CN108333365B (zh) 2018-01-24 2020-09-04 南开大学 金-长余辉纳米粒子免原位激发检测成纤维细胞激活蛋白
WO2019154859A1 (en) 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor
US11426472B2 (en) 2018-10-17 2022-08-30 Purdue Research Foundation Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis
GB201820320D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
BR112021011861A2 (pt) 2019-01-04 2021-09-08 Praxis Biotech LLC Inibidores da proteína de ativação de fibroblastos
CN110368496B (zh) 2019-07-11 2020-12-29 同济大学 成纤维细胞激活蛋白抑制剂在制备药物中的用途
CN111574634B (zh) 2019-12-16 2022-04-19 四川大学华西医院 同时靶向间皮素和fap的双靶点嵌合抗原受体及其用途
CN111235221B (zh) 2020-01-22 2022-08-05 北京大学第一医院 一种fap抑制剂的活性检测方法

Also Published As

Publication number Publication date
ES2972577T3 (es) 2024-06-13
CN110291401A (zh) 2019-09-27
US20200237936A1 (en) 2020-07-30
US20210316018A1 (en) 2021-10-14
EP3555627B1 (en) 2023-11-22
US20260048157A1 (en) 2026-02-19
EP3555627A1 (en) 2019-10-23
JP7162592B2 (ja) 2022-10-28
US11872291B2 (en) 2024-01-16
US20220105208A1 (en) 2022-04-07
US12397069B2 (en) 2025-08-26
JP2020502130A (ja) 2020-01-23
EP3555627A4 (en) 2020-08-19
WO2018111989A1 (en) 2018-06-21
CN110291401B (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
US11872291B2 (en) Fibroblast activation protein (FAP)-targeted imaging and therapy
US12508319B2 (en) Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof
US11141494B2 (en) Development of neurokinin-1 receptor-binding agent delivery conjugates
CN111225688B (zh) 靶向碳酸酐酶阳性癌症的基于fbsa的治疗和放射性成像缀合物
US10857234B2 (en) Carbonic anhydrase IX inhibitor conjugates and uses thereof
JP7027325B2 (ja) 炭酸無水酵素ｉｘを標的とする薬剤および方法
JP2018512390A (ja) Ｐｓｍａリガンド−チューブリシン化合物を用いた癌の処置方法
HK40016594B (en) Fibroblast activation protein (fap)-targeted imaging and therapy
HK40016594A (en) Fibroblast activation protein (fap)-targeted imaging and therapy
HK40016572B (en) Luteinizing hormone-releasing hormone receptor (lhrh-r) conjugates and uses thereof
HK40016572A (en) Luteinizing hormone-releasing hormone receptor (lhrh-r) conjugates and uses thereof
HK40031566B (zh) 靶向碳酸酐酶阳性癌症的基於fbsa的治疗和放射性成像缀合物
HK40031566A (en) Fbsa-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination